TCR Signal Strength and Eomes Coordinate CD8⁺ T Cell Fate and Antitumor Immunity in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) poses a persistent barrier to effective immunotherapy, in part due to the emergence of exhausted CD8+ T cells. Using a hydrodynamic, autochthonous HCC model based on Sleeping Beauty-mediated delivery of oncogenic drivers and defined OVA-derived antigens, we could manipulate antigen affinity under physiological priming conditions. With this system, we examined how TCR signal strength and the transcription factor Eomesodermin (Eomes) shape CD8+ T cell fate in vivo. High-affinity stimulation supported robust effector differentiation and the formation of tissue-resident memory T cells (Trm), resulting in early tumor control. In contrast, low-affinity stimulation induced elevated Eomes expression and favored rapid transition toward an exhausted (Tex) phenotype. Genetic repression of Eomes enhanced Trm differentiation in high-affinity CD8+ T cells and delayed tumor relapse, whereas ectopic Eomes expression accelerated exhaustion and led to earlier tumor recurrence. Under low-affinity conditions, Eomes deficiency increased the Trm-to-Tex ratio but remained insufficient to restore effective antitumor immunity, indicating that weak TCR engagement imposes constraints that cannot be overcome by Eomes loss alone. These findings reveal that the strength of TCR engagement shapes CD8+ T cell fate in HCC, while Eomes selectively biases this process toward exhaustion at the expense of effector and resident memory programs, ultimately influencing the durability of tumor control. SynopsisThis study reveals that the strength of T-cell receptor signaling fundamentally steers whether CD8+ T cells in liver cancer become durable tumor-fighting cells or slip into exhaustion, pinpointing Eomes as a key factor that pushes cells toward dysfunction. By uncovering how antigen affinity and Eomes jointly shape antitumor immunity, the work offers new conceptual and therapeutic avenues for improving the persistence and effectiveness of immunotherapies in hepatocellular carcinoma.